Lung Cancer Clinical Trials in Detroit

Showing 161-180 of 561 trials

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05783622

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck+4 more

Janux Therapeutics130 participantsStarted Apr 2023

Duarte, California, United States • Sacramento, California, United States • San Diego, California, United States +15 more locations

COMPLETEDPhase 2< 1 mile

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT02186847

This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Metformin hydrochloride may shrink tumors and keep them from coming back. It is not yet known whether chemotherapy and radiation therapy is more effective when given with or without metformin hydrochloride in treating stage III non-small cell lung cancer.

Adenosquamous Lung CarcinomaBronchioloalveolar CarcinomaLarge Cell Lung Carcinoma+6 more

NRG Oncology170 participantsStarted Aug 2014

Tuscaloosa, Alabama, United States • Tucson, Arizona, United States • Auburn, California, United States +221 more locations

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Other Conditions in Detroit